Guggenheim Sees Compass (CMPX) Potential Driven by Biliary Tract Cancer Pipeline

Compass Therapeutics Inc. (NASDAQ:CMPX) is one of the best multibagger stocks to invest in right now. The company’s lead program, CTX-009, is progressing through clinical trials for advanced solid tumors, particularly biliary tract cancer (BTC), where the company estimates a market opportunity exceeding $1 billion. Notably, Compass Therapeutics Inc. (NASDAQ:CMPX) is pointing out a significant unmet medical need, as around 85% of BTC patients who fail first-line therapy have no approved, effective treatment.

On that front, analyst Michael Schmidt of Guggenheim released an optimistic report. On August 12, the analyst raised his price target on Compass Therapeutics Inc. (NASDAQ:CMPX) to $12 from $10, and maintained a Buy rating. The call followed the release of Q2 results, which included encouraging pipeline updates and new clinical data.

Management updated guidance for the COMPANION-002 Phase 2/3 trial of tovecimig in biliary tract cancer. Final progression-free survival and overall survival data are now expected in early 2026, as opposed to the prior timeline of Q4 2025. While slightly later than planned, the trial remains on track and is viewed as a key near-term catalyst.

Schmidt cited stronger conviction in tovecimig and added probability-adjusted value from CTX-8371 as drivers of the higher target. Overall, the update reflects growing confidence in Compass Therapeutics Inc.’s (NASDAQ:CMPX) pipeline, which is beginning to show clearer signs of clinical and commercial potential.

Compass Therapeutics Inc. (NASDAQ:CMPX) is a clinical-stage biotechnology firm developing next-generation antibody therapies for cancer. Its lead programs, tovecimig and CTX-8371, target difficult-to-treat tumors.

While we acknowledge the potential of CMPX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Shorted Stocks Right Now and 10 Best High Beta Stocks To Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.